Pharsight

Mitsubishi Tanabe patents expiration

1. Radicava Ors patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11478450 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11826352 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage

RADICAVA ORS family patents

Family Patents